165 related articles for article (PubMed ID: 31511205)
21. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
22. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW
Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655
[TBL] [Abstract][Full Text] [Related]
23. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
Feng F; Jiang Q; Cao S; Cao Y; Li R; Shen L; Zhu H; Wang T; Sun L; Liang E; Sun H; Chai Y; Li X; Liu G; Yang R; Yang Z; Yang Y; Xin S; Li BA
Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):1017-1030. PubMed ID: 29369785
[TBL] [Abstract][Full Text] [Related]
24. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
Mao K; Zhang J; He C; Xu K; Liu J; Sun J; Wu G; Tan C; Zeng Y; Wang J; Xiao Z
Cancer Lett; 2014 Oct; 352(2):245-52. PubMed ID: 25034398
[TBL] [Abstract][Full Text] [Related]
25. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells.
Son Y; Shin NR; Kim SH; Park SC; Lee HJ
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069373
[TBL] [Abstract][Full Text] [Related]
26. Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Hua L; Hu B; Yan D; Liu J; Shen Y; Zhao F; Shen C; Chen B; Cui X
Pathol Res Pract; 2017 Jun; 213(6):688-697. PubMed ID: 28476378
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression.
Kim HY; Jung HU; Yoo SH; Yoo KS; Cheong J; Park BS; Yun I; Yoo YH
Cancer Lett; 2014 Dec; 355(1):61-9. PubMed ID: 25218348
[TBL] [Abstract][Full Text] [Related]
28. ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α.
Wu FQ; Fang T; Yu LX; Lv GS; Lv HW; Liang D; Li T; Wang CZ; Tan YX; Ding J; Chen Y; Tang L; Guo LN; Tang SH; Yang W; Wang HY
J Hepatol; 2016 Aug; 65(2):314-24. PubMed ID: 27154061
[TBL] [Abstract][Full Text] [Related]
29. Y-box binding protein 1 augments sorafenib resistance
Liu T; Xie XL; Zhou X; Chen SX; Wang YJ; Shi LP; Chen SJ; Wang YJ; Wang SL; Zhang JN; Dou SY; Jiang XY; Cui RL; Jiang HQ
World J Gastroenterol; 2021 Jul; 27(28):4667-4686. PubMed ID: 34366628
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
Chen KF; Chen HL; Shiau CW; Liu CY; Chu PY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Br J Pharmacol; 2013 Feb; 168(3):658-72. PubMed ID: 22978563
[TBL] [Abstract][Full Text] [Related]
31. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C
Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines.
Haga Y; Kanda T; Nakamura M; Nakamoto S; Sasaki R; Takahashi K; Wu S; Yokosuka O
PLoS One; 2017; 12(3):e0174153. PubMed ID: 28323861
[TBL] [Abstract][Full Text] [Related]
33. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
[TBL] [Abstract][Full Text] [Related]
34. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
35. Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.
Chen W; Xiao W; Zhang K; Yin X; Lai J; Liang L; Chen D
Sci Rep; 2016 Mar; 6():22976. PubMed ID: 26964667
[TBL] [Abstract][Full Text] [Related]
36. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.
Fernando J; Sancho P; Fernández-Rodriguez CM; Lledó JL; Caja L; Campbell JS; Fausto N; Fabregat I
J Cell Physiol; 2012 Apr; 227(4):1319-25. PubMed ID: 21604268
[TBL] [Abstract][Full Text] [Related]
38. Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway.
Tao NN; Zhou HZ; Tang H; Cai XF; Zhang WL; Ren JH; Zhou L; Chen X; Chen K; Li WY; Liu B; Yang QX; Cheng ST; Huang LX; Huang AL; Chen J
Oncotarget; 2016 Aug; 7(31):50117-50130. PubMed ID: 27367026
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
[TBL] [Abstract][Full Text] [Related]
40. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
